To date, most antibodies recognizing the SARS-CoV-2 spike (S) protein target the receptor binding domain (RBD). Three recent studies (Cerutti et al., 2021; McCallum et al., 2021; and Suryadevara et al., 2021) report on highly protective antibodies that are specific to the N-terminal domain (NTD) and target a conserved supersite.
Copyright © 2021 Elsevier Inc. All rights reserved.